We are live on ! Find out more
ADAP

Adaptimmune Therapeutics
ADAP

Delisted

ADAP was delisted on the 27th of October, 2025.

Back to rankings

76 hedge funds and large institutions have $631M invested in Adaptimmune Therapeutics in 2018 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 26 increasing their positions, 19 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 2 → 4 (+2)

81% more capital invested

Capital invested by funds: $348M → $631M (+$283M)

42% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 12

37% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 19

7% more funds holding

Funds holding: 71 → 76 (+5)

0.73% more ownership

Funds ownership: 9.26% → 9.99% (+0.73%)

27% less call options, than puts

Call options by funds: $721K | Put options by funds: $983K

Holders
76
Holders Change
+5
Holders Change %
+7.04%
% of All Funds
1.74%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.09%
New
17
Increased
26
Reduced
19
Closed
12
Calls
$721K
Puts
$983K
Net Calls
-$262K
Net Calls Change
-$312K

Top Buyers

Rank Fund Capital Flow
1
MCMC
Matrix Capital Management Company
New Hampshire
+$14.6M
2
NMC
NEA Management Company
Maryland
+$11.4M
3
Wellington Management Group
Wellington Management Group
Massachusetts
+$7.93M
4
Millennium Management
Millennium Management
New York
+$5.88M
5
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
+$5.64M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$9.17M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$7.03M
3
AG
Artal Group
Luxembourg
-$4.68M
4
GAMA
Graticule Asia Macro Advisors
New York
-$2.03M
5
Axa
Axa
France
-$1.98M
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$1.76M +$841K +96,119 +159%
AA
27
ALPS Advisors
Colorado
$1.41M +$191K +21,839 +21%
Lazard Asset Management
28
Lazard Asset Management
New York
$1.25M +$977K +111,682 New
BBA
29
Baker Bros. Advisors
New York
$1.12M – – –
PCM
30
Prelude Capital Management
New York
$1.12M +$357K +40,841 +69%
Creative Planning
31
Creative Planning
Kansas
$1.11M +$282K +32,219 +48%
ARTA
32
A.R.T. Advisors
New York
$953K +$743K +84,925 New
WMSA
33
Weiss Multi-Strategy Advisers
New York
$898K -$175K -20,000 -20%
GCP
34
GSA Capital Partners
United Kingdom
$852K +$664K +75,912 New
Arrowstreet Capital
35
Arrowstreet Capital
Massachusetts
$748K +$262K +29,977 +82%
Goldman Sachs
36
Goldman Sachs
New York
$625K -$278K -31,735 -36%
Susquehanna International Group
37
Susquehanna International Group
Pennsylvania
$611K +$476K +54,405 New
DADC
38
D.A. Davidson & Co
Montana
$569K -$12.5K -1,427 -3%
OAM
39
Oxford Asset Management
United Kingdom
$565K -$445K -50,795 -50%
Geode Capital Management
40
Geode Capital Management
Massachusetts
$485K +$127K +14,544 +51%
Squarepoint
41
Squarepoint
New York
$466K +$134K +15,300 +58%
State Street
42
State Street
Massachusetts
$424K -$557K -63,626 -63%
Barclays
43
Barclays
United Kingdom
$403K +$7.45K +851 +2%
BFM
44
Boothbay Fund Management
New York
$380K +$296K +33,851 New
D.E. Shaw & Co
45
D.E. Shaw & Co
New York
$352K -$440K -50,253 -62%
ProShare Advisors
46
ProShare Advisors
Maryland
$337K -$12.9K -1,479 -5%
Acadian Asset Management
47
Acadian Asset Management
Massachusetts
$309K +$99.7K +11,397 +71%
GIP
48
Granite Investment Partners
California
$291K -$847K -96,779 -79%
RJA
49
Raymond James & Associates
Florida
$282K +$70.5K +8,056 +47%
State of New Jersey Common Pension Fund D
50
State of New Jersey Common Pension Fund D
New Jersey
$270K – – –
1
2
3 4

ADAP Hedge Fund Activity: Q1 2018 in Review

76 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q1 2018, worth a combined $631M — up 81% from $348M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new ADAP positions and 12 closed out — a net gain of 5 holders — while 26 added to existing stakes and 19 trimmed.

The largest buyer was Matrix Capital Management Company, adding an estimated $14.6M. The largest seller was OrbiMed, cutting an estimated $9.17M.

  • 76 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q1 2018, up from 71 in Q4 2017.
  • Funds reported $631M of Adaptimmune Therapeutics stock for Q1 2018, up 81% quarter-over-quarter.
  • 17 funds opened new Adaptimmune Therapeutics positions in Q1 2018 and 12 closed out, a net change of +5 holders.
  • The largest Adaptimmune Therapeutics buyer in Q1 2018 was Matrix Capital Management Company, an estimated $14.6M added.
  • The largest Adaptimmune Therapeutics seller in Q1 2018 was OrbiMed, an estimated $9.17M sold.

Based on aggregated 13F filings for Q1 2018.